Prince Pharmaceutical Co (ROCO:6935) Other Current Receivables: NT$29 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6935 Prince Pharmaceutical Co Ltd ROCO:6935
60 GF Score
Price NT$29.65
GF Value NT$42.30
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Prince Pharmaceutical Co Other Current Receivables?

Prince Pharmaceutical Co ROCO:6935 60 Other Current Receivables is NT$29 Mil as of Dec. 2025. GuruFocus rates ROCO:6935 with a GF Score™ of 60/100 and a GF Value™ of NT$42.30 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Prince Pharmaceutical Co's Other Current Receivables for the quarter that ended in Dec. 2025 was NT$29 Mil.

Prince Pharmaceutical Co's quarterly Other Current Receivables increased from Dec. 2024 (NT$18.59 Mil) to Jun. 2025 (NT$25.86 Mil) and increased from Jun. 2025 (NT$25.86 Mil) to Dec. 2025 (NT$29.48 Mil).

Prince Pharmaceutical Co's annual Other Current Receivables declined from Dec. 2023 (NT$19.10 Mil) to Dec. 2024 (NT$18.59 Mil) but then increased from Dec. 2024 (NT$18.59 Mil) to Dec. 2025 (NT$29.48 Mil).

Prince Pharmaceutical Co Other Current Receivables Related Terms

Prince Pharmaceutical Co Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Prince Pharmaceutical Co's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prince Pharmaceutical Co Other Current Receivables Chart

Prince Pharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 8.99 15.55 19.10 18.59 29.48

Prince Pharmaceutical Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.10 18.31 18.59 25.86 29.48
ROCO:6935
60GF Score
Prince Pharmaceutical Co Ltd ROCO:6935
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prince Pharmaceutical Co Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of NT$29 Mil mean?
Prince Pharmaceutical Co (ROCO:6935) has a Other Current Receivables of NT$29 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Prince Pharmaceutical Co and its competitors.
Is Prince Pharmaceutical Co's Other Current Receivables too high?
Prince Pharmaceutical Co's current Other Current Receivables is NT$29 Mil. Overall, Prince Pharmaceutical Co has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prince Pharmaceutical Co's Other Current Receivables compare to ZTS?
Prince Pharmaceutical Co's Other Current Receivables of NT$29 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Prince Pharmaceutical Co and its competitors. Prince Pharmaceutical Co's current Other Current Receivables is NT$29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prince Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Prince Pharmaceutical Co (ROCO:6935) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$42.30, compared to a current price of NT$29.65 — trading 29.9% below its estimated fair value. The current Other Current Receivables is NT$29 Mil. Prince Pharmaceutical Co's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Prince Pharmaceutical Co (ROCO:6935), the current Other Current Receivables is NT$29 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prince Pharmaceutical Co (ROCO:6935) Overvalued in 2026?

Based on GuruFocus' analysis, Prince Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$29.65 is trading 29.9% below its estimated GF Value™ of NT$42.30. GuruFocus considers Prince Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for ROCO:6935:

  • Other Current Receivables: NT$29 Mil
  • GF Value™: NT$42.30 vs. price of NT$29.65 (29.9% below fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6935 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prince Pharmaceutical Co Business Description

Address Number 168, Keyunnan Road, Huwei Town, Yunlin, TWN, 632
Prince Pharmaceutical Co Ltd is engaged in the manufacturing, packaging, processing, and trading of various active pharmaceutical ingredients and health supplements. The company supplies its products to Taiwan, Japan, Spain, Europe and other regions.
60GF Score

Get the complete analysis for ROCO:6935

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$29.65
Price
NT$42.30
GF Value